Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters

Country/Region as subject
Publication year range
1.
BMC Public Health ; 18(1): 447, 2018 04 04.
Article in English | MEDLINE | ID: mdl-29615015

ABSTRACT

BACKGROUND: The prevalence of breast cancer has been increasing in sub-Saharan Africa over the last few years. Patients often present with late stage disease, resulting in a high mortality rate. This study aims to estimate the prevalence of breast -related symptoms in the female population of Burkina Faso. The findings can be used to advise on adequate diagnostic health services for breast symptoms to ensure early detection and down-staging of breast cancer. METHODS: A cross-sectional, population based study of 996 women was conducted to investigate the proportion of women with breast-related symptoms. A semi-structured questionnaire was used to collect sociodemographic data, information about breast cancer knowledge and details about breast-related symptoms, health care seeking and medical care. Breast-related symptoms were categorised as currently present/not currently present to estimate the current prevalence of women requiring a diagnostic service. RESULTS: Among the 996 women, 120 reported having had a breast-related symptom in their life. Only 36 women sought medical advice and eight women had diagnostic confirmation by histological or imaging techniques. Current breast-related symptoms were reported by 33 women (3.3% of the sample). An extrapolation to Burkina Faso's female population suggests that 184,562 women are in current need of diagnostic services due to any breast-related symptoms. CONCLUSIONS: Imaging techniques at the community and referral level are needed in order to triage women with breast-related symptoms. Specialised services need to be strengthened to ensure appropriate diagnosis and treatment of breast diseases. Education campaigns among the general population and among health care professionals are required to increase awareness of breast cancer and improve prompt health care seeking and referral.


Subject(s)
Breast Neoplasms/epidemiology , Diagnostic Services , Health Services Needs and Demand , Patient Acceptance of Health Care , Adolescent , Adult , Aged , Aged, 80 and over , Burkina Faso/epidemiology , Cross-Sectional Studies , Female , Humans , Middle Aged , Prevalence , Surveys and Questionnaires , Young Adult
2.
Article in German | MEDLINE | ID: mdl-27631446

ABSTRACT

Worldwide, post-partum haemorrhage (PHH) remains one of the leading causes for maternal mortality. The German Society of Gynaecology and Obstetrics, the German Midwifes' Society, the German Society of Thrombosis and Haemostasis and the German Society of Anaesthesiology and Intensive Care updated the former guideline. The resulting recommendations are the results of a structured literature search and a formal consensus process and contain all aspects of PPH including diagnosis, causes, risk factors and therapy. Key aspect of the anaesthesiological and haemostatic therapies is the development of an interdisciplinary standard operating procedure containing medical options related to the bleeding's cause and severity as well as the surgical option. For suspected PPH, this guideline emphasizes clinical and laboratory-based diagnostics, as only those will enable an early identification of the bleeding's causes and the resulting causative therapy. Recommendations cover evidence-based application of uterotonics for atony as well as tranexamic acid, calcium, factor concentrates and blood products. Additionally, recommendations are given on the topics of cell salvage, controlled hypotension and restrictive transfusion triggers.


Subject(s)
Blood Transfusion/standards , Clinical Laboratory Techniques/standards , Hemostatic Techniques/standards , Postpartum Hemorrhage/diagnosis , Postpartum Hemorrhage/therapy , Practice Guidelines as Topic , Evidence-Based Medicine , Germany , Gynecology/standards , Obstetrics/standards , Treatment Outcome
3.
Pathogens ; 12(12)2023 Nov 24.
Article in English | MEDLINE | ID: mdl-38133273

ABSTRACT

Based on epidemiological evidence and molecular findings, a possible association of Epstein-Barr virus (EBV) with the carcinogenesis of breast cancer has been described. However, the frequency of EBV in breast cancer and the role of EBV regarding tumor progression or therapeutic results is largely unexplored. Here, we report on two cases of advanced, lymph node-positive invasive breast cancer of no special type (NST), histologically showing no clinical or histological evidence of tumor regression as an equivalent of a lack of response to primary systemic therapy. Both tumors were considered to be EBV-associated due to their positivity in EBV-encoded RNA (EBER) in situ hybridization (ISH) and their immunoreactivity against EBV Epstein-Barr nuclear antigen 1 (EBNA1). We hypothesize that the unusual non-response to chemotherapy in these cases of breast cancer classified as triple-negative and HER2-positive may be linked to the EBV co-infection of tumor cells. Therefore, EBV tumor testing should be considered in patients with breast cancer presenting with resistance to chemotherapy. This hypothesis may provide a new aspect in the context of EBV-associated mechanisms of tumor progression.

4.
Anticancer Res ; 41(1): 485-496, 2021 Jan.
Article in English | MEDLINE | ID: mdl-33419847

ABSTRACT

BACKGROUND/AIM: Subcutaneous Herceptin (HER SC) has been shown to be equally effective and safe compared to intravenous Herceptin (HER i.v.) application in early HER2-positive breast cancer (HER2+ BC). However, real-world data from the subcutaneous application are currently limited. PATIENTS AND METHODS: Based on a non-interventional study (NIS), data from routine clinical use of HER SC have been gathered between 2013 and 2018 in 135 hospitals and open-care practices throughout Germany. RESULTS: A total of 265 patients were recruited in the neo-adjuvant and 605 patients in the adjuvant setting. Primary effectiveness endpoint in the neoadjuvant treatment setting was pathological complete response rate, which was achieved in 41.5%. Primary endpoint in the adjuvant setting was disease free survival rate after 2 years (94.9%). Safety results from the study were comparable to the well-known safety profile of HER i.v. including preferred terms, incidence, severity, including cardiac events. No new safety signals were detected. CONCLUSION: Effectiveness and safety of HER SC were comparable to data from HER i.v. in early HER2+ BC.


Subject(s)
Antineoplastic Agents, Immunological/administration & dosage , Breast Neoplasms/drug therapy , Breast Neoplasms/genetics , Receptor, ErbB-2/antagonists & inhibitors , Receptor, ErbB-2/genetics , Trastuzumab/administration & dosage , Adult , Aged , Aged, 80 and over , Antineoplastic Agents, Immunological/adverse effects , Biomarkers, Tumor , Breast Neoplasms/mortality , Breast Neoplasms/pathology , Chemotherapy, Adjuvant , Duration of Therapy , Female , Germany , Humans , Injections, Subcutaneous , Middle Aged , Molecular Targeted Therapy , Neoadjuvant Therapy , Neoplasm Grading , Neoplasm Staging , Polymerase Chain Reaction , Prognosis , Quality of Life , Retreatment , Trastuzumab/adverse effects , Treatment Outcome , Young Adult
5.
Geburtshilfe Frauenheilkd ; 80(8): 834-843, 2020 Aug.
Article in English | MEDLINE | ID: mdl-32817990

ABSTRACT

Objective The aim of this study was to determine the present oral health status of pregnant women depending on selected sociodemographic differences and deduce any resulting consequences for health prevention. Methods The participants' data of relevance to the study such as age, school leaving qualification, migration background, smoking habits or last dentist visit were recorded using a questionnaire. The subsequent dental check-up concentrated on open carious lesions, any initiated root canal treatments and missing teeth. Finally, the Periodontal Screening Index was recorded to diagnose the presence of any gingivitis or periodontitis. The subsequent biometric evaluation comprised descriptive data analysis, χ 2 test and logistical regression. Results The higher the school leaving qualification, the lower the probability that a pregnant woman smoked prior to pregnancy (OR 0.291; 95% CI 0.114 - 0.743) and that tartar was diagnosed (OR 0.424; 95% CI 0.185 - 0.973). Regular dentist visits (OR 4.026; 95% CI 1.613 - 10.049) increase with the attained school leaving qualification. There is a greater chance that women born in Germany taking part in the study were aware of dental risks in pregnancy (OR 2.652; 95% CI 1.285 - 5.472) and attended the dentist during pregnancy (OR 2.507; 95% CI 1.281 - 4.907). Conclusion The rate of awareness of the risks and consequences of pregnancy for oral health must be increased. The main aim for primary prophylaxis should be a reduction in the periodontal bacteria and caries of the mother and father.

6.
Geburtshilfe Frauenheilkd ; 78(4): 382-399, 2018 Apr.
Article in English | MEDLINE | ID: mdl-29720744

ABSTRACT

PURPOSE: This is an official interdisciplinary guideline, published and coordinated by the German Society of Gynaecology and Obstetrics (DGGG), the Austrian Society of Gynaecology and Obstetrics (OEGGG) and the Swiss Society of Gynaecology and Obstetrics (SGGG). The guideline was developed for use in German-speaking countries and is backed by the German Society of Anaesthesiology and Intensive Medicine (DGAI), the Society of Thrombosis and Haemostasis Research (GTH) and the German Association of Midwives. The aim is to provide a consensus-based overview of the diagnosis and management of peripartum bleeding obtained from an evaluation of the relevant literature. METHODS: This S2k guideline was developed from the structured consensus of representative members of the various professional associations and professions commissioned by the Guideline Commission of the DGGG. RECOMMENDATIONS: The guideline encompasses recommendations on definitions, risk stratification, prevention and management.

7.
Integr Med (Encinitas) ; 15(3): 34-9, 2016 Jun.
Article in English | MEDLINE | ID: mdl-27547165

ABSTRACT

CONTEXT: Postmarketing surveillance data for a commercially available extract of Rheum rhaponticum (ERr 731) have not been published since the beginning of the reporting in 1993 in Germany about adverse events (AEs) that were believed to be associated with it. The extract is derived from the plant's roots and is indicated for menopausal relief. In Germany, the extract has been marketed as Phytoestrol N and other related products-Phyto-Strol, Phyto-Strol Loges, and Phyto-Strol compact and as femi-loges. In the United States and Canada and in South Africa, the product had been marketed as Estrovera. OBJECTIVE: The study's objective was to summarize the AE reports from Germany from 1993 to June 2014 and also to assess consumers' complaints in North America and South Africa from the date of the extract's launch to June 2014. DESIGN: AE reports recorded by 2 German holders of marketing authorizations, Chemisch-Pharmazeutische Fabrik Göppingen, for Phytoestrol N, and Dr. Loges + Co. GmbH, for femi-loges, were collected and analyzed. Consumers' complaints in North America and South Africa that had been captured by the US distributor of Estrovera were also collected and analyzed. RESULTS: From 1993 to June 2014, approximately 140 million daily doses of the extract were placed on the German market, and 124 AE reports were recorded. The most common of those AEs were hypersensitivity, with 74 reactions, and gastrointestinal symptoms, with 47 reactions. From January 2009 to June 2014, approximately 13 million tablets of the supplement were sold in North America, and 79 complaints from consumers associated with a physical response to it had been recorded. The main complaints were gastrointestinal symptoms, with 23 cases, and failure to work as suggested, with 22 cases. From the date of the product's launch in South Africa in February 2011 to June 2014, no consumer complaints have been reported. CONCLUSIONS: The records related to postmarketing surveillance and consumers' complaints suggest that the extract of R rhaponticum is generally safe for consumption.

8.
Infect Dis Poverty ; 5(1): 81, 2016 Sep 01.
Article in English | MEDLINE | ID: mdl-27581074

ABSTRACT

BACKGROUND: Because infections with Schistosoma Haematobium usually peak in childhood, the majority of studies on schistosomiasis have focused on school-aged children. This study aimed to assess the epidemiological and clinical aspects of urogenital schistosomiasis in women in Burkina Faso, West Africa. METHODS: A cross-sectional study was conducted in a mesoendemic region (Kombissiri) and a hyperendemic region (Dori) for schistosomiasis in Burkina Faso. A total of 287 females aged 5 to 50 years were included in the study. S. haematobium infection was assessed using the urine filtration method and dipsticks were used for the detection of hematuria. Interviews were conducted to identify clinical aspects and risk factors related to urogenital schistosomiasis. RESULTS: The overall prevalence of S. haematobium infection in Dori was 21.3 %, where as Kombissiri was less affected with a prevalence of 4.6 %. The most affected age group was the 10- to 14-year-olds (41.2 %), followed by the 15- to 19-year-olds (26.3 %). Risk factors significantly associated with schistosomiasis (P <0.05) were place of residence, age, contact with open water in the past year, and distance of home to open water. The percentage of participants who had contact with open water was significantly higher among the women living in Dori compared to Kombissiri. Females over 15 years of age showed a significant higher rate of water contact compared to the 5- to 15-year-olds. A significant correlation between schistosomiasis and hematuria was established. Microhematuria showed a sensitivity of 80.6 %, a specificity of 92.7 %, and a positive predictive value of 61.7 %, whereas macrohematuria had a sensitivity of 47.2 %, a specificity of 99.2 %, and a positive predictive value of 89.5 %. The mass distribution of praziquantel in Burkina Faso is well established. However, over half of the participants with schistosomiasis in this study said they took praziquantel in the past 6 months, which indicates a high reinfection rate. This may be associated with a lack of knowledge about the transmission of schistosomiasis. Only 6 % of the participants in Kombissiri and 1.5 % in Dori knew about the correct mode of transmission. CONCLUSIONS: The results of our study indicate that distribution campaigns should be extended from school-aged children to young women. Our data also demonstrate the necessity of combining already established mass distribution campaigns with information campaigns, so that long-term elimination, or at least reduction, of schistosomiasis can be achieved.


Subject(s)
Praziquantel/therapeutic use , Schistosoma haematobium/physiology , Schistosomiasis haematobia/epidemiology , Schistosomiasis haematobia/pathology , Schistosomicides/therapeutic use , Adolescent , Adult , Age Factors , Animals , Burkina Faso/epidemiology , Child , Child, Preschool , Cross-Sectional Studies , Female , Health Knowledge, Attitudes, Practice , Humans , Middle Aged , Morbidity , Prevalence , Risk Factors , Schistosomiasis haematobia/drug therapy , Schistosomiasis haematobia/psychology , Young Adult
9.
Trop Doct ; 45(2): 105-13, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25505190

ABSTRACT

OBJECTIVES: How traditional birth attendants (TBAs) in post-war Sierra Leone explain, handle and prevent postpartum haemorrhage (PPH) and their potential role in a better management of PPH to reduce maternal mortality in this low resource setting. METHODS: Semi-quantitative interviews about knowledge and measures in PPH and participant observation with 140 Sierra Leonean birth attendants, divided in three groups: (A) TBAs who never attended any official training course (n = 82); (B) TBAs who attended at least one official training course (n = 48); and (C) officially trained birth attendants (n = 10). RESULTS: There are several observable gaps in the knowledge of TBAs about PPH compared to modern obstetrics, however similar procedures exist. Herbal medicine is applied; metaphysical convictions about PPH remain present. Training courses show an impact. Officially trained birth attendants demonstrate knowledge deficiencies and lack resources and infrastructure to manage PPH adequately. CONCLUSIONS: Morbidity and mortality of PPH in Sierra Leone is related to several factors and not solely to the ignorance of TBAs. TBAs still play an important role for many women there. Hence improvement of the formal health sector should be combined with life-saving programmes integrating TBAs in the care for the pregnant, delivering and breastfeeding mothers.


Subject(s)
Clinical Competence , Health Knowledge, Attitudes, Practice , Midwifery/standards , Obstetrics/methods , Postpartum Hemorrhage/therapy , Adult , Female , Herbal Medicine/methods , Humans , Maternal Mortality , Midwifery/education , Postpartum Hemorrhage/prevention & control , Pregnancy , Sierra Leone , Warfare
10.
Breast Care (Basel) ; 3(1): 10-16, 2008.
Article in English | MEDLINE | ID: mdl-20824014

ABSTRACT

For 2010, the annual incidence of breast cancer is estimated to increase from now 1.15 Mio to 1.5 Mio new cases per year. The increase is mainly seen in low and middle income countries. Resource limitations in means of finance, personnel, infrastructure, and by political instability are tremendous. Currently, little attention is paid to breast care in low-resource settings due to other health priorities. However, with increasing life expectancy and reduction of mortality due to infectious diseases, more people are confronted with non-communicable diseases, and the topic of cancer in developing countries will emerge more and more. Specific guidelines for breast cancer were given by the Global Breast Health Initiative differentiating according to available resources in different settings. From awareness in public and health care facilities to obtaining the diagnosis, deciding on strategies of treatment, and putting strategies into practice - all these obstacles differ substantially in developed and developing countries. Further research is essential to meet the challenge of breast cancer worldwide in the coming years.

SELECTION OF CITATIONS
SEARCH DETAIL